Progress toward development of photodynamic vaccination against infectious/malignant diseases and photodynamic mosquitocides

Kwang Poo Chang, Bala K. Kolli, Chia Kwung Fan, Dennis K.P. Ng, Clarence T.T. Wong, Laura Manna, Raffaele Corso, Neng Yao Shih, Robert Elliott, X. P. Jiang, Shin Hong Shiao, Guo Liang Fu

研究成果: 書貢獻/報告類型會議貢獻

1 引文 (Scopus)

摘要

Photodynamic therapy (PDT) uses photosensitizers (PS) that are excited with light to generate ROS in the presence of oxygen for treating various diseases. PS also has the potential use as photodynamic insecticides (PDI) and for light-inactivation of Leishmania for photodynamic vaccination (PDV). PDT-inactivated Leishmania are non-viable, but remain immunologically competent as whole-cell vaccines against leishmaniasis, and as a universal carrier for delivery of add-on vaccines against other infectious and malignant diseases. We have screened novel PS, including Zn-and Si-phthalocyanines (PC) for differential PDT activities against Leishmania, insect and mammalian cells in vitro to assess their PDI and PDV potential. Here, Zn-PC were conjugated with various functional groups. The conjugates were examined for uptake by cells as a prerequisite for their susceptibility to light-inactivation. PDT sensitivity was found to vary with cell types and PS used. PDI potential of several PS was demonstrated by their mosquito larvicidal PDT activities in vitro. PDT-inactivated Leishmania were stored frozen for PDV in several ongoing studies: [1] Open label trial with 20 sick dogs for immunotherapy of canine leishmaniasis after chemotherapy in Naples, Italy. Clinical follow-up for >3 years indicate that the PDV prolongs their survival; [2] PDV of murine models with a human lung cancer vaccine showed dramatic tumor suppression; [3] Open label trial of multiple PDV via compassionate access to 4 advanced cancer patients showed no clinically adverse effects. Two subjects remain alive. Genetic modifications of Leishmania are underway to further enhance their safety and efficacy for PDV by installation of activable mechanisms for self-destruction and spontaneous light-emission.
原文英語
主出版物標題Light-Based Diagnosis and Treatment of Infectious Diseases
發行者SPIE
10479
ISBN(電子)9781510614437
DOIs
出版狀態已發佈 - 一月 1 2018
事件Light-Based Diagnosis and Treatment of Infectious Diseases 2018 - San Francisco, 美国
持續時間: 一月 29 2018一月 31 2018

會議

會議Light-Based Diagnosis and Treatment of Infectious Diseases 2018
國家美国
城市San Francisco
期間1/29/181/31/18

指紋

Photodynamic therapy
infectious diseases
Photosensitizing Agents
Photosensitizers
Photochemotherapy
Communicable Diseases
therapy
Vaccination
Leishmania
insecticides
vaccines
Insecticides
Vaccines
Light
deactivation
Labels
cancer
cells
Leishmaniasis Vaccines
Cancer Vaccines

ASJC Scopus subject areas

  • Electronic, Optical and Magnetic Materials
  • Biomaterials
  • Atomic and Molecular Physics, and Optics
  • Radiology Nuclear Medicine and imaging

引用此文

Chang, K. P., Kolli, B. K., Fan, C. K., Ng, D. K. P., Wong, C. T. T., Manna, L., ... Fu, G. L. (2018). Progress toward development of photodynamic vaccination against infectious/malignant diseases and photodynamic mosquitocides. 於 Light-Based Diagnosis and Treatment of Infectious Diseases (卷 10479). [1047912] SPIE. https://doi.org/10.1117/12.2281437

Progress toward development of photodynamic vaccination against infectious/malignant diseases and photodynamic mosquitocides. / Chang, Kwang Poo; Kolli, Bala K.; Fan, Chia Kwung; Ng, Dennis K.P.; Wong, Clarence T.T.; Manna, Laura; Corso, Raffaele; Shih, Neng Yao; Elliott, Robert; Jiang, X. P.; Shiao, Shin Hong; Fu, Guo Liang.

Light-Based Diagnosis and Treatment of Infectious Diseases. 卷 10479 SPIE, 2018. 1047912.

研究成果: 書貢獻/報告類型會議貢獻

Chang, KP, Kolli, BK, Fan, CK, Ng, DKP, Wong, CTT, Manna, L, Corso, R, Shih, NY, Elliott, R, Jiang, XP, Shiao, SH & Fu, GL 2018, Progress toward development of photodynamic vaccination against infectious/malignant diseases and photodynamic mosquitocides. 於 Light-Based Diagnosis and Treatment of Infectious Diseases. 卷 10479, 1047912, SPIE, Light-Based Diagnosis and Treatment of Infectious Diseases 2018, San Francisco, 美国, 1/29/18. https://doi.org/10.1117/12.2281437
Chang KP, Kolli BK, Fan CK, Ng DKP, Wong CTT, Manna L 等. Progress toward development of photodynamic vaccination against infectious/malignant diseases and photodynamic mosquitocides. 於 Light-Based Diagnosis and Treatment of Infectious Diseases. 卷 10479. SPIE. 2018. 1047912 https://doi.org/10.1117/12.2281437
Chang, Kwang Poo ; Kolli, Bala K. ; Fan, Chia Kwung ; Ng, Dennis K.P. ; Wong, Clarence T.T. ; Manna, Laura ; Corso, Raffaele ; Shih, Neng Yao ; Elliott, Robert ; Jiang, X. P. ; Shiao, Shin Hong ; Fu, Guo Liang. / Progress toward development of photodynamic vaccination against infectious/malignant diseases and photodynamic mosquitocides. Light-Based Diagnosis and Treatment of Infectious Diseases. 卷 10479 SPIE, 2018.
@inproceedings{11fcb81b53224ba5ab3b7b72e1c91ba3,
title = "Progress toward development of photodynamic vaccination against infectious/malignant diseases and photodynamic mosquitocides",
abstract = "Photodynamic therapy (PDT) uses photosensitizers (PS) that are excited with light to generate ROS in the presence of oxygen for treating various diseases. PS also has the potential use as photodynamic insecticides (PDI) and for light-inactivation of Leishmania for photodynamic vaccination (PDV). PDT-inactivated Leishmania are non-viable, but remain immunologically competent as whole-cell vaccines against leishmaniasis, and as a universal carrier for delivery of add-on vaccines against other infectious and malignant diseases. We have screened novel PS, including Zn-and Si-phthalocyanines (PC) for differential PDT activities against Leishmania, insect and mammalian cells in vitro to assess their PDI and PDV potential. Here, Zn-PC were conjugated with various functional groups. The conjugates were examined for uptake by cells as a prerequisite for their susceptibility to light-inactivation. PDT sensitivity was found to vary with cell types and PS used. PDI potential of several PS was demonstrated by their mosquito larvicidal PDT activities in vitro. PDT-inactivated Leishmania were stored frozen for PDV in several ongoing studies: [1] Open label trial with 20 sick dogs for immunotherapy of canine leishmaniasis after chemotherapy in Naples, Italy. Clinical follow-up for >3 years indicate that the PDV prolongs their survival; [2] PDV of murine models with a human lung cancer vaccine showed dramatic tumor suppression; [3] Open label trial of multiple PDV via compassionate access to 4 advanced cancer patients showed no clinically adverse effects. Two subjects remain alive. Genetic modifications of Leishmania are underway to further enhance their safety and efficacy for PDV by installation of activable mechanisms for self-destruction and spontaneous light-emission.",
keywords = "canine leishmaniasis, compassionate trial, immunotherapy, Leishmania, List: Photosensitizer, lung cancer, mouse tumor model, photo-inactivation, phthalocyanine, porphyrin, singlet oxygen, vaccination, vaccine carrier, vaccine safety",
author = "Chang, {Kwang Poo} and Kolli, {Bala K.} and Fan, {Chia Kwung} and Ng, {Dennis K.P.} and Wong, {Clarence T.T.} and Laura Manna and Raffaele Corso and Shih, {Neng Yao} and Robert Elliott and Jiang, {X. P.} and Shiao, {Shin Hong} and Fu, {Guo Liang}",
year = "2018",
month = "1",
day = "1",
doi = "10.1117/12.2281437",
language = "English",
volume = "10479",
booktitle = "Light-Based Diagnosis and Treatment of Infectious Diseases",
publisher = "SPIE",

}

TY - GEN

T1 - Progress toward development of photodynamic vaccination against infectious/malignant diseases and photodynamic mosquitocides

AU - Chang, Kwang Poo

AU - Kolli, Bala K.

AU - Fan, Chia Kwung

AU - Ng, Dennis K.P.

AU - Wong, Clarence T.T.

AU - Manna, Laura

AU - Corso, Raffaele

AU - Shih, Neng Yao

AU - Elliott, Robert

AU - Jiang, X. P.

AU - Shiao, Shin Hong

AU - Fu, Guo Liang

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Photodynamic therapy (PDT) uses photosensitizers (PS) that are excited with light to generate ROS in the presence of oxygen for treating various diseases. PS also has the potential use as photodynamic insecticides (PDI) and for light-inactivation of Leishmania for photodynamic vaccination (PDV). PDT-inactivated Leishmania are non-viable, but remain immunologically competent as whole-cell vaccines against leishmaniasis, and as a universal carrier for delivery of add-on vaccines against other infectious and malignant diseases. We have screened novel PS, including Zn-and Si-phthalocyanines (PC) for differential PDT activities against Leishmania, insect and mammalian cells in vitro to assess their PDI and PDV potential. Here, Zn-PC were conjugated with various functional groups. The conjugates were examined for uptake by cells as a prerequisite for their susceptibility to light-inactivation. PDT sensitivity was found to vary with cell types and PS used. PDI potential of several PS was demonstrated by their mosquito larvicidal PDT activities in vitro. PDT-inactivated Leishmania were stored frozen for PDV in several ongoing studies: [1] Open label trial with 20 sick dogs for immunotherapy of canine leishmaniasis after chemotherapy in Naples, Italy. Clinical follow-up for >3 years indicate that the PDV prolongs their survival; [2] PDV of murine models with a human lung cancer vaccine showed dramatic tumor suppression; [3] Open label trial of multiple PDV via compassionate access to 4 advanced cancer patients showed no clinically adverse effects. Two subjects remain alive. Genetic modifications of Leishmania are underway to further enhance their safety and efficacy for PDV by installation of activable mechanisms for self-destruction and spontaneous light-emission.

AB - Photodynamic therapy (PDT) uses photosensitizers (PS) that are excited with light to generate ROS in the presence of oxygen for treating various diseases. PS also has the potential use as photodynamic insecticides (PDI) and for light-inactivation of Leishmania for photodynamic vaccination (PDV). PDT-inactivated Leishmania are non-viable, but remain immunologically competent as whole-cell vaccines against leishmaniasis, and as a universal carrier for delivery of add-on vaccines against other infectious and malignant diseases. We have screened novel PS, including Zn-and Si-phthalocyanines (PC) for differential PDT activities against Leishmania, insect and mammalian cells in vitro to assess their PDI and PDV potential. Here, Zn-PC were conjugated with various functional groups. The conjugates were examined for uptake by cells as a prerequisite for their susceptibility to light-inactivation. PDT sensitivity was found to vary with cell types and PS used. PDI potential of several PS was demonstrated by their mosquito larvicidal PDT activities in vitro. PDT-inactivated Leishmania were stored frozen for PDV in several ongoing studies: [1] Open label trial with 20 sick dogs for immunotherapy of canine leishmaniasis after chemotherapy in Naples, Italy. Clinical follow-up for >3 years indicate that the PDV prolongs their survival; [2] PDV of murine models with a human lung cancer vaccine showed dramatic tumor suppression; [3] Open label trial of multiple PDV via compassionate access to 4 advanced cancer patients showed no clinically adverse effects. Two subjects remain alive. Genetic modifications of Leishmania are underway to further enhance their safety and efficacy for PDV by installation of activable mechanisms for self-destruction and spontaneous light-emission.

KW - canine leishmaniasis

KW - compassionate trial

KW - immunotherapy

KW - Leishmania

KW - List: Photosensitizer

KW - lung cancer

KW - mouse tumor model

KW - photo-inactivation

KW - phthalocyanine

KW - porphyrin

KW - singlet oxygen

KW - vaccination

KW - vaccine carrier

KW - vaccine safety

UR - http://www.scopus.com/inward/record.url?scp=85046423839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046423839&partnerID=8YFLogxK

U2 - 10.1117/12.2281437

DO - 10.1117/12.2281437

M3 - Conference contribution

VL - 10479

BT - Light-Based Diagnosis and Treatment of Infectious Diseases

PB - SPIE

ER -